Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

Abstract

Background: In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted. Patients with cancer were considered at high risk on sparse evidence, and despite a small number of emerging observational studies, the true incidence and impact of COVID-19 in the 'at-risk' population of patients with cancer is yet to be defined. Methods: Epidemiological and clinical data were collected prospectively for patients attending the Royal Marsden Hospital and three network hospitals between March 1st and April 30th 2020 that were confirmed to have Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Significance of clinical and pathological characteristics was assessed using the Fisher's exact test and Wilcoxon rank sum test, whilst univariate and multivariate logistic regression models were used to further assess risk. The number of patients attending in March/ April 2020 for face-to-face attendances was also extracted. Findings: During the 2-month study period, 867 of 13,489 (6.4%) patients met the criteria leading to swab testing. Of the total at-risk population, only 113 of 13,489 (0.84%) were swab positive, 101 of 13,489 (0.75%) required hospital admission and 29 of 13,489 (0.21%) died of

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

“…[ 30 ] Conference proceedings 137 20 14 Mar to 15 Apr 2020 Gustave Roussy Cancer Campus, Villejuif, France Any 23 Angelis et al. [ 31 ] Peer reviewed 113 29 1 Mar to 30 Apr 2020 Royal Marsden, London, UK Any 24 Gupta et al. [ 32 ] Peer reviewed 112 60 4 Mar to 4 Apr 2020 65 hospitals, USA Any 25 Zhang et al [ 33 ] Peer reviewed 107 23 5 Jan to 18 Mar 2020 5 hospitals from Wuhan, China Any 26 Deng et al.…”

Patient Satisfaction with Oncological Care during the SARS-CoV-2 Virus Pandemic

“…The epidemiological situation resulting from the pandemic has had a significant impact on oncological care. Patients hospitalized due to the need for cancer treatment are a special group at risk of COVID-19 and the severe course of this disease [ 21 ].…”

Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study

“…While it appears in these examples that defects in antibody or T-cell response are compensated by the other adaptive immunity arm, patients with haematological malignancies were still at higher risk of ICU admission (albeit based on small numbers), and two received tocilizumab, which may have aided their recovery. All the patients in our cohort recovered, while 11/18 patients with haematological malignancies died due to COVID-19 at our institution (Angelis et al, 2020), before enrolment into CAPTURE commenced. Thus, it is possible that the patients with haematological malignancy in our interim analysis cohort are not entirely representative of the spectrum of immune dysfunction in this group, which we continue to interrogate through ongoing recruitment and posthumous access to stored samples from those who died.…”